OGN — Organon & Co · P/E 3.4, rev $3.02B

Organon & Co (OGN) is a drug manufacturers - general company listed on US.

Latest reported OGN revenue for 2026-06-30 was $3.02B. Net income was $254.0M. OGN currently screens at market cap $2.52B and trailing P/E 3.4.

Use this OGN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the OGN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the OGN SEC filings page. Lician reads the product cache first so this HTML stays unique to Organon & Co even when a live quote feed is slow.

Organon & Co latest statements (FY2025)

Latest cached year on this hub. Full OGN income, balance, and cash tables.

  • Revenue$6.22B
  • Net Income$187.0M
  • Total Assets$12.87B
  • Total Debt$0
  • Free Cash Flow$538.0M

OGN recent filings